# A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia

> **NCT02973191** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Celgene**

## Conditions studied

- Precursor Cell Lymphoblastic Leukemia-Lymphoma

## Interventions

- **DRUG:** JCAR015

## Key facts

- **NCT ID:** NCT02973191
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-12-20
- **Primary completion:** 2019-06-25
- **Final completion:** 2021-01-24
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Development of JCAR015 has been discontinued. No subjects were enrolled/treated under protocol JCAR015-ALL-001
- **Last updated:** 2017-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02973191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02973191, "A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02973191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*